Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2086359 | 0.87 | AOC3 (0.42) | CYP1A2CYP2C19NPC1USP2RAB9A | |
| SCHEMBL29561785 | 0.73 | KMT2A (0.43) | DPP4NPC1USP2RAB9ASMN1; SMN2 | |
| SCHEMBL21060577 | 0.73 | KMT2A (0.43) | DPP4NPC1USP2RAB9ASMN1; SMN2 | |
| SCHEMBL2085198 | 0.71 | CCR1 (0.39) | CYP1A2CYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL18132257 | 0.69 | HDAC4 (0.47) | CYP1A2CYP2C9CYP2C19NPC1L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL5389154 | 0.68 | AGPAT2 (0.60) | HTR2C | |
| SCHEMBL2492253 | 0.66 | TSHR (0.44) | CYP2C19NPC1USP2RAB9ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL2086389 | 0.66 | MAPK1 (0.50) | NPC1RAB9AL3MBTL1TSHRALDH1A1 | |
| SCHEMBL2085154 | 0.66 | KDM4E (0.43) | CYP1A2CYP2C19NPC1RAB9ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL2081865 | 0.65 | L3MBTL1 (0.49) | CYP1A2CYP2C9CYP2C19HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863269-B2 | protease-activated receptor 1 (PAR1) inhibitors such as 1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3-iminoimidazo[1,5-a]pyridin-2-yl)ethanone, used as anticoagulants | SANOFI-AVENTIS (FR) | 2011-01-04 | — | — | US | disclosed |
| EP-2054412-B1 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | SANOFI AVENTIS (FR) | 2009-12-02 | — | — | EP | disclosed |
| US-20090192150-A1 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2009-07-30 | — | — | US | disclosed |
| EP-2054412-A2 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | Sanofi-Aventis (FR) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008014888-A2 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192150-A1 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | F2R, TFPI, F2RL1 | DPP4 134/4885RXRA 2225/4885RXRB 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.